Comparison of the pregnancy outcomes of the patients with severe symptoms who received medical treatment for COVID-19 versus the patients with mild-moderate symptoms

Abstract

Objective COVID-19 has spread all over the world since December 2019. There is little evidence concerning maternal or perinatal outcomes up to now. The present study aimed to compare pregnant women with severe and mild-moderate COVID-19 symptoms in terms of maternal and perinatal outcomes. Methods The study group was composed of pregnant patients admitted to our tertiary center with symptoms and diagnosed with severe acute respiratory syndrome Coronavirus 2 (SARS-Cov-2). The patients were categorized into two groups: severe and not severe, and women determined as in the severe disease group were hospitalized. The patients were continued to their routine follow-up, their maternal and perinatal outcomes were recorded. Results A total of 52 patients were enrolled in the study: 59.6% presented mild-moderate disease and 40.4% presented severe disease. The gestational age at diagnosis of COVID-19 was higher in the patients with severe symptoms than in patients with mild-moderate symptoms (median 20.5 vs 28.0, respectively, p=0.048). There was no difference between those two groups in terms of maternal and perinatal outcomes. Conclusion Despite the growing number of published studies on COVID-19 in pregnancy, there are insufficient quality data to draw conclusions about the severity of COVID-19 in symptomatic pregnant women and its maternal and neonatal consequences. In our study, there is no difference between mild-moderate and severe groups in terms of maternal and perinatal outcomes.

Maternal and neonatal outcomes of pregnant women with SARS-CoV-2 infection in our tertiary hospital

“…According to these groups, the symptoms were respectively as follows; fever 28.6% and 9.5%, myalgia 64.5% and 66.7%, cough 60.7% and 61.9%, loss of taste 41.9% and 14.3%, and dyspnea 3.2% and 19.0%. [14] In the study of fiahin et al, the symptoms were as follows: fever 27.6%, cough 58.6%, dyspnea 34.5%, chest pain 3.4%, myalgia 51.7%, nasal congestion 13.8%, sore throat 37.9%, anosmia 31%, ageusia 20.7%, headache 24.1%, nausea/vomiting 20.7%, and diarrhea 3.4%. [1] In our study, the symptoms were as follows: dyspnea 32.6%, fever 17.39%, cough 13.04%, visual impairment 4.34%, and respiratory failure and tachypnea 2.17%.…”

“…Today, WHO and American College of Obstetricians and Gynecologists (ACOG) recommends Coronavirus vaccine for all pregnant and postpartum women. [14] Symptomatology has an important place in the follow-up and treatment of both pregnant and non-pregnant patients infected with COVID-19. [15] In the study of Yüksel et al conducted in our country, pregnant women infected with COVID-19 were divided into two groups according to their symptoms as mild-moderate symptoms and severe symptoms.…”

“…[20] In the study conducted by Yüksel et al conducted in our country, the rate of hospitalization in ICU and pregnant women with severe symptoms were 12.9% and 14.3%, respectively. [14] Follow-up of 6 (13.04%) pregnant women who had a severe course of the disease and needed additional treatment was performed in the Anesthesia ICU.…”

Maternal mortality cases due to COVID-19 pandemic in a tertiary referral hospital

“…[19] Most of the relevant studies reported that admissions to the neonatal unit aimed to isolate the infants from their mothers, the COVID-19-related neonatal mortality rate was very low, and there was no direct connection between the six deaths (three intrauterine deaths and three neonatal deaths) and COVID-19. [19,27,36] Di Toro et al found positive nasopharyngeal swabs in 19 newborns, but it was considered to have been due to contamination rather than an intrauterine infection, since the swabs were not taken immediately after birth, and viral RNA could not be detected in the cord or neonatal blood samples. [19] In this study, the mean 1-minute and 5-minute Apgar scores were 6.15±1.52 and 7.92±0.76, respectively.…”